Start-Up Quarterly Statistics, Q1 2011
This article was originally published in Start Up
Biopharma and medical device start-ups brought in a total of $216 million in Q1 2011. Absent were any financings involving in vitro diagnostics companies. Only four acquisitions involving start-ups were completed - one in biopharma and three in the device industry. Cancer was the most popular therapeutic category among biopharma start-up alliance this quarter.
You may also be interested in...
The founders of PanOptica are inspired by the big impact VEGF-inhibitors originally developed for cancer are having on the ophthalmic market. So much so, that they company aims to search out compounds from other disease areas such as cancer, diabetes and other metabolic disorders, and find those likely to have potential for serious eye disorders.
Receptos isn't the only company in the G-coupled protein receptor oral MS drug arena, but it believes its proprietary S1P1 agonist will improve on Novartis' first-in-class S1P1 modulator Gilenya. Unlike Gilenya, which hits four of the five S1P receptor subtypes, the Receptos molecule binds selectively to S1P1 and has a predicted human half-life of approximately one day, potentially improving the safety profile and reducing complications for MS patients.
Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer’s disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it’s becoming clear that advances in AD diagnostics could play a major role in reducing that risk.